Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on September 9, 2021. The filing reports on a material definitive agreement entered into on the same date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a disclosure of a contractual amendment rather than a periodic financial report.
Material Changes
On September 9, 2021, Codexis, Inc. and Merck, Sharp & Dohme Corp. executed Amendment No. 5 to their Sitagliptin Catalyst Supply Agreement, originally dated February 1, 2021. The primary material change is the extension of the Agreement's term to December 31, 2026.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the agreement but provides no specific financial guidance or outlook. Management directs investors to the Company's Annual Report on Form 10-K (filed March 1, 2021) and Quarterly Report on Form 10-Q (filed August 6, 2021) for a description of risks and uncertainties that could cause actual results to differ from expectations.
Key Facts for Investor Verification
- Verify the full text of Amendment No. 5 to the Sitagliptin Catalyst Supply Agreement, expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2021.
- Confirm the new expiration date of the agreement is December 31, 2026.
- Review the press release attached as Exhibit 99.1 for additional context on the partnership with Merck.
- Consult the most recent Form 10-K and 10-Q for financial performance and risk factors not detailed in this 8-K.